论文部分内容阅读
随着改革开放的深入,新药研究与开发(R & D)作为推动我国医药工业发展的战略决策已经提到重要议事日程。为借鉴国外先进经验,尽快缩小差距,提高我国新药R & D水平,国家医药管理局新药研究管理中心和美国协尔公司(Shared Enterprise),宾夕法尼亚大学(Pennsylvania University)于1996年12月联合举办了“新药研究与开发赴美培训班”。由于承担了二项“国家新药基金项目”,我有幸参加培训,获益非浅。由于培训内容太多,在此只能就这次培训的内容作一简介。
With the deepening of reform and opening up, the research and development (R & D) of new drugs as a strategic decision to promote the development of China’s pharmaceutical industry have already mentioned the important agenda. In order to draw lessons from advanced foreign experience, we can shorten the gap as soon as possible and improve the R & D level of new drugs in our country. The State Pharmaceutical Administration New Drug Research and Management Center and the United States Shared Enterprise, the University of Pennsylvania jointly held in December 1996 “New Drug Research and Development Training Course to the United States.” As a result of having undertaken two “National New Drug Fund Projects”, I was fortunate enough to attend the training and benefited greatly. Due to too much training, here only a brief introduction of the content of this training.